Skip to main content

Table 4 Patient demographics and oncological characteristics of patients started on SACT between 1st March to 31st May in 2020 during COVID-19 (with 2019 as a comparator)

From: Safe provision of systemic anti-cancer treatment for urological cancer patients during COVID-19: a tertiary centre experience in the first wave of COVID-19

  2019 (n = 118) 2020 (n = 102) (n2020n2019)/n2019 (%) p value
n % n %
Sex       N
 Male 106 89.83 90 88.24 15.09 0.705
Age
 Mean (SD)—years 66.92 (12.16) 65.12 (13.23)
Socioeconomic status (IMD)
 Low 37 31.36 40 39.22 − 8.11 0.223
 Middle 43 36.44 28 27.45 34.88 0.155
 High 38 32.20 33 32.35 13.16 0.981
 Missing 0 0.00 1 0.98 N.A 0.281
Ethnicity
 White British 44 37.29 29 28.43 34.09 0.164
 White Other 9 7.63 9 8.82 0.00 0.747
 Black Caribbean 9 7.63 5 4.90 44.44 0.409
 Black African 3 2.54 4 3.92 − 33.33 0.561
 Black Other 0 0.00 1 0.98 N.A 0.281
 Asian 1 0.85 0 0.00 100.00 0.351
 Mixed 1 0.85 0 0.00 100.00 0.351
 Other 1 0.85 1 0.98 0.00 0.917
 Unknown 50 42.37 53 51.96 − 6.00 0.155
Performance status (ECOG)
 0 42 35.59 27 26.47 35.71 0.134
 1 62 52.54 61 59.80 1.61 0.271
 2 13 11.02 3 2.94 76.92 0.0214
 3 1 0.85 0 0.00 100.00 0.368
 Missing 0 0.00 11 10.78 N.A 0.000216*
Cancer type
 Prostate 74 62.71 57 55.88 22.97 0.303
 Renal 22 18.64 21 20.59 4.55 0.717
 Urothelial 14 11.86 17 16.67 − 21.43 0.307
 Testicular 8 6.78 7 6.86 12.50 0.981
Stage       
 1 7 5.93 1 0.98 85.71 0.0504
 2 4 3.39 5 4.90 − 25.00 0.572
 3 7 5.93 4 3.92 42.86 0.495
 4 100 84.75 92 90.20 8.00 0.226
 Missing 0 0.00 0 0.00 N.A
SACT       
 Chemotherapy 58 49.15 27 26.47 53.45 0.000674*
 Immunotherapy 15 12.71 18 17.65 − 20.00 0.230
  PD-1/L1 11 9.32 15 14.71 − 36.36
  PD-1/L1 + CTLA-4 3 2.54 4 3.92 − 33.33
  Vaccine 1 0.85 0 0.00 100.00
 Hormone 33 27.97 43 42.16 − 30.30 0.0278
  Novel hormone agents 33 27.97 41 40.20 − 24.24
 Biological/targeted 11 9.32 12 11.76 − 9.09 0.689
 Combo (Chemo/hormone) 1 0.85 1 0.98 0.00 0.920
 Combo (IO/target) 0 0.00 1 0.98 N.A 0.271
Treatment paradigm       
 Neoadjuvant 8 6.78 4 3.92 50.00 0.368
 Adjuvant 10 8.47 2 1.96 80.00 0.0357
 Radical 4 3.39 0 0.00 100.00 0.0574
 Palliative 95 80.51 90 88.24 5.26 0.110
 Curative 1 0.85 6 5.88 − 500.00 0.0357
Line of palliative treatment (2019, n = 95; 2020, n = 90)       
 1 24 20.34 28 27.45 − 16.67 0.376
 2 49 41.53 50 49.02 − 2.04 0.588
 3 14 11.86 8 7.84 42.86 0.219
 4 5 4.24 2 1.96 60.00 0.279
 5 2 1.69 1 0.98 50.00 0.593
 6 0 0.00 1 0.98 N.A 0.303
 7 1 0.85 0 0.00 100.00 0.329
Trial treatment       
 Yes 7 5.93 3 2.94 57.14 0.288
30-day mortality 2 1.69 1 0.98 50.00 0.649
6-month mortality 11 9.32 2 1.96 81.82 0.0209*
  1. *Statistically significant p values after Bonferroni correction for multiple comparisons